REMEGEN CO. LTD YC 1 (REG) - Total Assets
Based on the latest financial reports, REMEGEN CO. LTD YC 1 (REG) holds total assets worth €7.25 Billion EUR (≈ $8.47 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is REMEGEN CO. LTD YC 1's book value for net asset value and shareholders' equity analysis.
REMEGEN CO. LTD YC 1 - Total Assets Trend (2021–2025)
This chart illustrates how REMEGEN CO. LTD YC 1's total assets have evolved over time, based on quarterly financial data.
REMEGEN CO. LTD YC 1 - Asset Composition Analysis
Current Asset Composition (December 2025)
REMEGEN CO. LTD YC 1's total assets of €7.25 Billion consist of 54.9% current assets and 45.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.9% |
| Accounts Receivable | €422.77 Million | 5.8% |
| Inventory | €661.49 Million | 9.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €152.48 Million | 2.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how REMEGEN CO. LTD YC 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see REMEGEN CO. LTD YC 1 market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: REMEGEN CO. LTD YC 1's current assets represent 54.9% of total assets in 2025, a decrease from 55.3% in 2021.
- Cash Position: Cash and equivalents constituted 15.9% of total assets in 2025, down from 42.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 9.1% of total assets.
REMEGEN CO. LTD YC 1 Competitors by Total Assets
Key competitors of REMEGEN CO. LTD YC 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
REMEGEN CO. LTD YC 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 1.05 | 1.51 |
| Quick Ratio | 1.19 | 0.75 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.19 Billion | €101.70 Million | €845.45 Million |
REMEGEN CO. LTD YC 1 - Advanced Valuation Insights
This section examines the relationship between REMEGEN CO. LTD YC 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.98 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 31.8% |
| Total Assets | €7.25 Billion |
| Market Capitalization | $2.31 Billion USD |
Valuation Analysis
Below Book Valuation: The market values REMEGEN CO. LTD YC 1's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: REMEGEN CO. LTD YC 1's assets grew by 31.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for REMEGEN CO. LTD YC 1 (2021–2025)
The table below shows the annual total assets of REMEGEN CO. LTD YC 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €7.25 Billion ≈ $8.47 Billion |
+31.82% |
| 2024-12-31 | €5.50 Billion ≈ $6.43 Billion |
-0.54% |
| 2023-12-31 | €5.53 Billion ≈ $6.46 Billion |
-8.19% |
| 2022-12-31 | €6.02 Billion ≈ $7.04 Billion |
+44.77% |
| 2021-12-31 | €4.16 Billion ≈ $4.86 Billion |
-- |
About REMEGEN CO. LTD YC 1
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Ve… Read more